🔓
Sign in as a Member to unlock the full view of BCRX. · Full hedge fund list, every line-item carveout, cabinet conflicts, and politicians-trading detail.
Become a Member$29.99/mo already a Member? Sign in →
BCRX

BioCryst Pharmaceuticals, Inc.

Sector: healthcareBiotechnologyNASDAQMarket Cap: $1.57B

BioCryst is a small-cap specialty pharma focused on rare diseases with minimal direct government dependence but subject to standard FDA/Medicare regulatory oversight.

Next filing → your inbox
Govt Dependence
25/100
Regulatory Density
65/100
Lobbying Intensity
5/100
Political Signal
LOW

BusinessWhat BCRX does

BioCryst Pharmaceuticals develops and commercializes therapies for rare genetic diseases, including hereditary angioedema (HAE) and other conditions. Revenue is primarily driven by specialty pharmaceutical sales to hospitals, specialty pharmacies, and patient assistance programs, with limited Medicare/Medicaid exposure relative to large-cap pharma.

12 months past · 3 months futureBCRX activity timeline

$11$9$6 DecJan '26FebMarAprMayJunJulAugSepOctNovDecJan '27Feb ↓ PAST — recorded activity ↑ FUTURE — scheduled markups · pending votes TODAY · Nov 17 $11.11 hi $6.24 lo $7.45 CONGRESS 9 INSIDERS 0 13F FUNDS 30 BILLS 5 Gilbert Ray Cisneros (D) · Purchase · 2026-07-09Gilbert Ray Cisneros (D) · Purchase · 2026-07-10 Two Sigma Investments · + $68M · 2026-06-30Two Sigma Investments · + $61M · 2026-03-31Two Sigma Investments · holds $35M · 2025-12-31Renaissance Technologies · + $25M · 2026-06-30AQR Capital Management · + $22M · 2026-06-30Citadel Advisors · + $21M · 2026-06-30Renaissance Technologies · - $17M · 2026-09-30Renaissance Technologies · holds $17M · 2025-12-31Citadel Advisors · + $12M · 2026-03-31Citadel Advisors · + $8M · 2025-12-31Renaissance Technologies · - $7M · 2026-03-31Bridgewater Associates · + $6M · 2026-03-31D.E. Shaw & Co. · - $5M · 2025-12-31Bridgewater Associates · - $5M · 2026-06-30 MARKUP · Senate Veterans' Affairs · 2026-11-18MARKUP · Senate Finance · 2026-11-18MARKUP · Senate Health, Education, Labor, and Pensions · 2026-11-18MARKUP · Senate Budget · 2026-11-18MARKUP · Senate Veterans' Affairs · 2026-11-18
Congress
buy sell
Insider · Form 4
open-market buy
Hedge fund · 13F
opened + added − trimmed closed holds
Bills
past action (this ticker) upcoming markup (sector) ★ carveout (this ticker)
250 trading days · 2 congressional trades shown · 0 insider buys · 14 13F filings · 0 past bill actions · 5 upcoming markups

Lifetime Government AwardsBCRX federal contracts

BCRX doesn't hold direct federal contracts.

Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.

Smart Money · 13F HoldingsHedge funds holding BCRX

$140.1M
Total BCRX held by tracked 13F funds
7
Funds with BCRX positions
+1
Funds opened this quarter
Two Sigma Investments $68M +6% 2 overlap 2026-06-30
AQR Capital Management $22M +403% 2 overlap 2026-06-30
Citadel Advisors $21M +76% 2 overlap 2026-06-30
Renaissance Technologies $17M -18% 2 overlap 2026-09-30
Bridgewater Associates $5M -23% 2 overlap 2026-06-30
D.E. Shaw & Co. $4M +35% 2 overlap 2026-06-30
Point72 Asset Management $3M opened 2 overlap 2026-06-30

Politicians Trading BCRXMembers of Congress with recent BCRX positions

1 politicians traded BCRX across 3 disclosed transactions totaling $24K (last 730 days). Greed score = composite of trade frequency, volume & recency across the politician's entire history (not just BCRX). 0-30 LOW · 30-60 MID · 60+ HIGH.

Congressional TradesWho in Congress is trading BCRX

2026-07-09 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000 57d late
2026-07-10 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000 56d late
2025-11-13 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2023-10-16 Josh Gottheimer D-New Jersey · house purchase $1,001 - $15,000
2023-10-16 Josh Gottheimer D-New Jersey · house Purchase $1,001 - $15,000
2023-09-15 Josh Gottheimer D-New Jersey · house sale $1,001 - $15,000
2023-09-15 Josh Gottheimer D-New Jersey · house Sale $1,001 - $15,000
2022-08-11 Josh Gottheimer D-New Jersey · house purchase $1,001 - $15,000
2022-08-11 Josh Gottheimer D-New Jersey · house Purchase $1,001 - $15,000
9+ trades on file · most recent 2026-09-04

Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock

Stock awards & option exercises

5
stock awards · $49K market value
2026-08-31 Frank Steven Director AWARD 1,288 sh $12K
2026-08-31 Milne Jill C. Director AWARD 1,288 sh $12K
2026-08-31 MILANO VINCENT Director AWARD 1,159 sh $11K
2026-08-31 McKee Amy E Director AWARD 644 sh $6K
2026-08-31 Stonehouse Jon P Director AWARD 644 sh $6K
For BCRX, executives receive stock primarily as compensation rather than via open-market purchases — typical for established large-cap firms.

Bills to WatchLegislation flagged by our analysis

Orphan Drug Act amendmentsMedicare drug pricing reformPDUFA reauthorization

Political ProfileWhere BCRX sits in Washington

BioCryst has minimal lobbying footprint, no named legislative winners/losers, and rare-disease focus insulates it from broad pharma pricing debates. Stock moves primarily on clinical/commercial data, not policy.

Regulatory ExposureThreats & opportunities

Regulatory threats

  • FDA approval delays
  • Medicare coverage restrictions
  • drug pricing pressure

Regulatory opportunities

  • Orphan drug exclusivity extension
  • Rare disease tax credits
  • Expedited FDA pathways
Member intelligence layer

Live signals + predictions for BCRX — for Founders

The free page above gives you the public record. Members see the real-time intelligence layer on top of it:

Become a Founder · $29.99/mo Locked rate forever · cancel anytime

Frequently AskedAbout BCRX & political exposure

Does BioCryst Pharmaceuticals, Inc. (BCRX) hold federal contracts?
No direct prime contracts reported in USASpending.gov for BioCryst Pharmaceuticals, Inc.. Companies in the semiconductor and AI hardware sectors often sell to the federal government via prime contractors and cloud resellers (Microsoft Azure, AWS, Lockheed Martin systems integration) rather than as direct primes.
Has Congress traded BCRX stock?
9 congressional trades by 2 unique members of Congress, most recently on 2026-07-10. See the Congressional Trading panel for politician-by-politician breakdown.
What is BCRX political risk profile?
Government dependence: 25/100. Lobbying intensity: 5/100. Political signal: low.
How does GovGreed track BCRX political activity?
GovGreed integrates STOCK Act congressional trade disclosures, FEC contributions, OGE executive-branch disclosures, USASpending federal contracts, Senate LDA lobbying filings, and SEC Form 4 corporate insider trades into a single queryable graph. BCRX data is updated daily from these official federal sources.